

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SS\$PTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS	4	APR 07	STN is raising the limits on saved answers
NEWS	5	APR 24	CA/CAPLUS now has more comprehensive patent assignee information
NEWS	6	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS	7	APR 28	CAS patent authority coverage expanded
NEWS	8	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS	9	APR 28	Limits doubled for structure searching in CAS REGISTRY
NEWS	10	MAY 08	STN Express, Version 8.4, now available
NEWS	11	MAY 11	STN on the Web enhanced
NEWS	12	MAY 11	BEILSTEIN substance information now available on STN Easy
NEWS	13	MAY 14	DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format
NEWS	14	MAY 15	INPADOCDB and INPAFAMDB enhanced with Chinese legal status data
NEWS	15	MAY 28	CAS databases on STN enhanced with NANO super role in records back to 1992
NEWS	16	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS	17	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS	18	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS	19	JUN 29	EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS	20	JUL 09	PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 11:25:28 ON 13 JUL 2009

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 11:25:50 ON 13 JUL 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JUL 2009 HIGHEST RN 1161919-42-1

DICTIONARY FILE UPDATES: 12 JUL 2009 HIGHEST RN 1161919-42-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10580670.str



```

chain nodes :
15 16 17 18 19 20 21 22 23 26 29 30 31
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
5-22 6-29 9-15 10-30 11-15 13-16 16-17 16-23 17-18 18-19 19-20 19-26
20-21 21-31
ring bonds :
1-2 1-7 2-3 3-4 4-8 5-6 5-9 6-7 7-8 8-9 10-11 10-14 11-12 12-13 13-14

exact/norm bonds :
5-6 5-22 6-7 10-11 10-14 16-17 16-23 19-26 21-31
exact bonds :
5-9 6-29 8-9 9-15 10-30 11-12 11-15 12-13 13-14 13-16 17-18 18-19 19-20
20-21
normalized bonds :
1-2 1-7 2-3 3-4 4-8 7-8
isolated ring systems :
containing 1 : 10 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 26:CLASS 29:CLASS 30:CLASS
31:CLASS


```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:26:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 11:26:16 FILE 'REGISTRY'


FULL SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10580670a.str



```

chain nodes :
15 16 17 18 19 20 21 22 23 26 29 30
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
5-22 6-29 9-15 10-30 11-15 13-16 16-17 16-23 17-18 18-19 19-20 19-26
20-21
ring bonds :
1-2 1-7 2-3 3-4 4-8 5-6 5-9 6-7 7-8 8-9 10-11 10-14 11-12 12-13 13-14
exact/norm bonds :
5-6 5-22 6-7 10-11 10-14 16-17 16-23 19-26
exact bonds :
5-9 6-29 8-9 9-15 10-30 11-12 11-15 12-13 13-14 13-16 17-18 18-19 19-20
20-21
normalized bonds :
1-2 1-7 2-3 3-4 4-8 7-8
isolated ring systems :
containing 1 : 10 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 26:CLASS 29:CLASS 30:CLASS

```


L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR

10580670



Structure attributes must be viewed using STN Express query preparation.

=> s l4

SAMPLE SEARCH INITIATED 11:28:57 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s l4 sss full

FULL SEARCH INITIATED 11:29:05 FILE 'REGISTRY'


FULL SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L6 0 SEA SSS FUL L4

=>

Uploading C:\Program Files\Stnexp\Queries\10580670b.str



```

chain nodes :
15 16 17 18 19 20 21 22 23 26 29 30
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
5-22 6-29 9-15 10-30 11-15 13-16 16-17 16-23 17-18 18-19 19-20 19-26
20-21
ring bonds :
1-2 1-7 2-3 3-4 4-8 5-6 5-9 6-7 7-8 8-9 10-11 10-14 11-12 12-13 13-14
exact/norm bonds :
5-6 5-22 6-7 10-11 10-14 16-17 16-23 19-26
exact bonds :
5-9 6-29 8-9 9-15 10-30 11-12 11-15 12-13 13-14 13-16 17-18 18-19 19-20
20-21
normalized bonds :
1-2 1-7 2-3 3-4 4-8 7-8
isolated ring systems :
containing 1 : 10 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 26:CLASS 29:CLASS 30:CLASS

```


L7 STRUCTURE UPLOADED

=> d l7

L7 HAS NO ANSWERS

L7 STR

10580670




Structure attributes must be viewed using STN Express query preparation.

=> d 17

L7 HAS NO ANSWERS

L7 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 17

SAMPLE SEARCH INITIATED 11:30:46 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 66 TO ITERATE

100.0% PROCESSED 66 ITERATIONS

46 ANSWERS

SEARCH TIME: 00.00.01

10580670

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 833 TO 1807
PROJECTED ANSWERS: 514 TO 1326


L8 46 SEA SSS SAM L7

=> s l8 sss full
FULL SEARCH INITIATED 11:30:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1271 TO ITERATE

100.0% PROCESSED 1271 ITERATIONS 853 ANSWERS
SEARCH TIME: 00.00.01

L9 853 SEA SSS FUL L7

=>
Uploading C:\Program Files\Stnexp\Queries\10580670d.str



chain nodes :
15 16 17 18 19 20 21 22 23 26 29 30 32
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
5-22 6-29 9-15 10-30 11-15 13-16 16-17 16-23 17-18 18-19 19-20 19-26
20-21 21-32
ring bonds :
1-2 1-7 2-3 3-4 4-8 5-6 5-9 6-7 7-8 8-9 10-11 10-14 11-12 12-13 13-14
exact/norm bonds :
5-6 5-22 6-7 10-11 10-14 16-17 16-23 19-26 21-32
exact bonds :
5-9 6-29 8-9 9-15 10-30 11-12 11-15 12-13 13-14 13-16 17-18 18-19 19-20
20-21
normalized bonds :
1-2 1-7 2-3 3-4 4-8 7-8
isolated ring systems :
containing 1 : 10 :

10580670

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 26:CLASS 29:CLASS 30:CLASS
32:CLASS

L10 STRUCTURE UPLOADED

=> d l10

L10 HAS NO ANSWERS

L10 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l10

SAMPLE SEARCH INITIATED 11:32:28 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 58 TO ITERATE

100.0% PROCESSED 58 ITERATIONS

34 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 704 TO 1616

PROJECTED ANSWERS: 331 TO 1029

L11 34 SEA SSS SAM L10

=> s l10 sss full

FULL SEARCH INITIATED 11:32:34 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1068 TO ITERATE

10580670



100.0% PROCESSED 1068 ITERATIONS
SEARCH TIME: 00.00.01

520 ANSWERS

L12 520 SEA SSS FUL L10

=>

Uploading C:\Program Files\Stnexp\Queries\10580670x.str



chain nodes :
15 16 17 18 19 20 21 22 23 26 29 30 32 34
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
5-22 6-29 9-15 10-30 11-15 13-16 16-17 16-23 17-18 18-19 19-20 19-26
20-21 21-32 21-34
ring bonds :
1-2 1-7 2-3 3-4 4-8 5-6 5-9 6-7 7-8 8-9 10-11 10-14 11-12 12-13 13-14
exact/norm bonds :
5-6 5-22 6-7 10-11 10-14 16-17 16-23 19-26 21-32 21-34
exact bonds :
5-9 6-29 8-9 9-15 10-30 11-12 11-15 12-13 13-14 13-16 17-18 18-19 19-20
20-21
normalized bonds :
1-2 1-7 2-3 3-4 4-8 7-8
isolated ring systems :
containing 1 : 10 :

G1:CH,NH2,Cy,Hy,Ak,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 26:CLASS 29:CLASS 30:CLASS
32:CLASS 34:CLASS
10580670.trn 10/13/2009 Page 11


10580670

L13 STRUCTURE UPLOADED

=> d l13

L13 HAS NO ANSWERS

L13 STR



G1 CH,NH2,Cy,Hy,Ak,N

Structure attributes must be viewed using STN Express query preparation.

=> s l13

SAMPLE SEARCH INITIATED 11:36:19 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 58 TO ITERATE

100.0% PROCESSED 58 ITERATIONS

34 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 704 TO 1616

PROJECTED ANSWERS: 331 TO 1029

L14 34 SEA SSS SAM L13

=> s l13 sss full

FULL SEARCH INITIATED 11:36:31 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1068 TO ITERATE

100.0% PROCESSED 1068 ITERATIONS

513 ANSWERS

SEARCH TIME: 00.00.01

L15 513 SEA SSS FUL L13

=> FIL HCAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

935.64

935.86

FILE 'HCAPLUS' ENTERED AT 11:36:37 ON 13 JUL 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jul 2009 VOL 151 ISS 3

FILE LAST UPDATED: 12 Jul 2009 (20090712/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 11:25:28 ON 13 JUL 2009)

FILE 'REGISTRY' ENTERED AT 11:25:50 ON 13 JUL 2009

```

L1      STRUCTURE UPLOADED
L2      0 S L1
L3      0 S L1 SSS FULL
L4      STRUCTURE UPLOADED
L5      0 S L4
L6      0 S L4 SSS FULL
L7      STRUCTURE UPLOADED
L8      46 S L7
L9      853 S L8 SSS FULL
L10     STRUCTURE UPLOADED
L11     34 S L10
L12     520 S L10 SSS FULL
L13     STRUCTURE UPLOADED
L14     34 S L13

```

10580670

L15 513 S L13 SSS FULL

FILE 'HCAPLUS' ENTERED AT 11:36:37 ON 13 JUL 2009

=> s l15

L16 4 L15

=> s l16 and py<=2003
24035901 PY<=2003

L17 0 L16 AND PY<=2003

=> d l16 ibib abs tot

L16 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1342422 HCAPLUS

DOCUMENT NUMBER: 146:81764

TITLE: Enhanced indolinone based protein kinase inhibitors
and their preparation, pharmaceutical compositions and
use in the treatment of cancer

INVENTOR(S): Liang, Congxin; Feng, Yangbo; Vojkovsky, Tomas

PATENT ASSIGNEE(S): The Scripps Research Institute, USA

SOURCE: U.S. Pat. Appl. Publ., 78pp., Cont.-in-part of Appl.
No. PCT/US2004/39725.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060287381	A1	20061221	US 2006-441537	20060526
WO 2005053686	A1	20050616	WO 2004-US39752	20041126
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:


WO 2004-US39752	A2	20041126
US 2005-685144P	P	20050526
US 2005-754360P	P	20051228
US 2003-525430P	P	20031126
US 2004-545721P	P	20040218

OTHER SOURCE(S): MARPAT 146:81764

GI



I



II

AB Hydroxy carboxy pyrrolyl-indolinone derivs. of formula I have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer. More particularly, alpha-hydroxy-omega-(2-oxo-indolylidenemethyl-pyrrole-3'-carbonyl) amino alkanolic acid and amide derivs. have enhanced and unexpected drug properties as inhibitors of protein kinases with respect to their corresponding beta-hydroxy-omega-(2-oxo-indolylidenemethyl-pyrrole-3'-carbonyl) amino alkanolic acid and amide derivs. and are useful in treating disorders related to abnormal protein kinase activities such as cancer. Compound of formula I wherein R1 and R2 are independently H, halo, C1-6 (halo)alkyl, C3-8 cycloalkyl, OH, amino, etc.; R3 is H, C1-6 alkyl, C6-10 aryl, C5-10 heteroaryl, and amide; R3 - R6 are independently H and C1-6 alkyl; R7 is H, C1-6 alkyl, and OH; R8 is OH, C1-6 O-alkyl, C3-8 cycloalkyl and NH2 and derivs., etc.; n and m are independently 0, 1, 2, and 3; and their pharmaceutically acceptable salts, tautomers, and prodrugs thereof, are claimed. Example compound II was prepared by amidation of (S)-4-([5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carbonyl]amino)-2-hydroxybutyric acid with (R)-3-hydroxypyrrolidine. All the invention compds. were evaluated for their protein kinase inhibitory activity. From the assay, it was determined that compound II exhibited and IC50 value of < 0.003 μ M.

L16 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1252701 HCAPLUS

DOCUMENT NUMBER: 146:27724

TITLE: Preparation of (pyrrolylmethylidene)indolinones as protein kinase inhibitors for the treatment of cancer
 Inventor(s): Liang, Congxin; Feng, Yangbo; Vojtkovsky, Tomas
 Patent Assignee(s): The Scripps Research Institute, USA
 Source: PCT Int. Appl., 49pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:


English

FAMILY ACC. NUM. COUNT:


6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006127961	A1	20061130	WO 2006-US20363	20060526
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006249790	A1	20061130	AU 2006-249790	20060526
CA 2610067	A1	20061130	CA 2006-2610067	20060526
EP 1893194	A1	20080305	EP 2006-771248	20060526
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2008542294	T	20081127	JP 2008-513740	20060526
MX 2007014810	A	20080221	MX 2007-14810	20071126
IN 2007DN09747	A	20080620	IN 2007-DN9747	20071217
KR 2008017058	A	20080225	KR 2007-730412	20071226
CN 101222920	A	20080716	CN 2006-80025908	20080115
PRIORITY APPLN. INFO.:			US 2005-685144P	P 20050526
			US 2005-754360P	P 20051228
			WO 2006-US20363	W 20060526
OTHER SOURCE(S):		CASREACT 146:27724; MARPAT 146:27724		
GI				



I



II

AB α -Hydroxy- ω -[5-(2-oxo-indol-3-ylidenemethyl)pyrrol-3-ylcarbonylamino]alkanoic acids and their derivs. I [wherein R1, R2 = H, halo, alkyl, etc.; R3 = H, alkyl, (hetero)aryl or amide; R4 - R6 = H or alkyl; R7 = OH, O-(alkyl), O-(cyclo)alkyl or (un)substituted amino; n = 1-3] and pharmaceutically acceptable salts, tautomers and prodrugs thereof were prepared as protein kinase inhibitors. For instance, II (R = OH) was synthesized via successive treatment of the corresponding pyrrolecarboxylic acid with HATU, amidation of the resultant active ester with Me (2S)-4-amino-2-hydroxybutyrate hydrochloride, and ester hydrolysis. Further amidation of acid II (R = OH) with amines led to a number of amides, such as II (R = NMe2, III). III had an IC50 of < 0.003 μ M against KDR in VEGFR biochem. assay. Therefore, the invented compds. are useful in treating disorders related to abnormal protein kinase activities such as cancer.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:523281 HCAPLUS

DOCUMENT NUMBER: 143:59818

TITLE: Preparation of 2-[(2-oxo-1,2-dihydro-indol-3-ylidene)methyl]pyrrole-4-carboxamide derivatives as protein kinase inhibitors

INVENTOR(S): Liang, Congxin

PATENT ASSIGNEE(S): The Scripps Research Institute, USA

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2




DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053686	A1	20050616	WO 2004-US39752	20041126
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20060287381	A1	20061221	US 2006-441537	20060526
MX 2006006050	A	20070524	MX 2006-6050	20060526
PRIORITY APPLN. INFO.:			US 2003-525430P	P 20031126
			US 2004-545721P	P 20040218
			WO 2004-US39752	A2 20041126
			US 2005-685144P	P 20050526
			US 2005-754360P	P 20051228
OTHER SOURCE(S):		CASREACT 143:59818; MARPAT 143:59818		
GI				



AB The title compds. (I) [wherein R1 = H, halo, C1-6 alkyl, C3-8 cycloalkyl, C1-6 haloalkyl, HO, C1-6 alkoxy, NH2, C1-6 alkylamino, amide, sulfonamide, cyano, (un)substituted C6-10 aryl; R2 = H, halo, C1-6 alkyl, C3-8 cycloalkyl, C1-6 haloalkyl, HO, C1-6 alkoxy, C2-8 alkoxyalkyl, NH2, C1-6 alkylamino, C6-10 arylamino; R3 = H, C1-6 alkyl, C6-10 aryl, C5-10

heteroaryl, amide; R4-R6 = H, C1-6 alkyl; R7 = H, C1-6 alkyl, HO; R8 = HO, C1-6 alkoxy, C3-8 cycloalkoxy, NR9R10 (where R9, R10 = H, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 dihydroxyalkyl, C1-6 alkoxy, C1-6 alkylcarboxylic acid, C1-6 alkylphosphoric acid, C1-6 alkylsulfuric acid, C1-6 hydroxyalkylcarboxylic acid, C1-6 alkyl amide, C3-8 cycloalkyl, C5-8 heterocycloalkyl, C6-8 aryl, C5-8 heteroaryl, C3-8 cycloalkylcarboxylic acid; or NR9R10 together forms (un)substituted (C5-C8) heterocyclic; n, m = 0-3; p = 1-3) or pharmaceutically acceptable salts, their tautomers, pharmaceutically acceptable salts of their tautomer, or prodrugs thereof are prepared. These compounds have enhanced and unexpected drug properties as inhibitors of protein kinases, in particular VEGF receptors and PDGF receptors, and are useful in treating disorders related to abnormal protein kinase activities such as cancer (no data). Thus, 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid was condensed with (4R,6R)-[6-(2-aminoethyl)-2,2-dimethyl-1,3]dioxan-4-yl]acetic acid tert-Bu ester using 3-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride and hydroxybenzotriazole in DMF at room temperature for 30 h followed by treatment with a mixture of 2 N aqueous HCl, THF, and EtOH, neutralization with aqueous NaHCO₃, extraction with Me tert-Bu ether to give (3R,5R)-7-[[5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carbonyl]amino]-3,5-dihydroxyheptanoic acid tert-Bu ester which was stirred with a mixture of aqueous NaOH solution and MeOH at room temperature for 3 h to give (3R,5R)-7-[[5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carbonyl]amino]-3,5-dihydroxyheptanoic acid sodium salt (II).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER:

2005:523237 HCAPLUS

DOCUMENT NUMBER:

143:59816

TITLE:

Preparation of advanced indolinone based protein kinase inhibitors

INVENTOR(S):

Liang, Congxin

PATENT ASSIGNEE(S):

The Scripps Research Institute, USA

SOURCE:

PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053614	A2	20050616	WO 2004-US39728	20041126
WO 2005053614	A3	20060223		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,			

SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

AU 2004294981	A1	20050616	AU 2004-294981	20041126
CA 2547066	A1	20050616	CA 2004-2547066	20041126
EP 1686987	A2	20060809	EP 2004-812287	20041126





R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
HR, IS, YU

CN 1905869	A	20070131	CN 2004-80040854	20041126
BR 2004016994	A	20070206	BR 2004-16994	20041126
JP 2007512353	T	20070517	JP 2006-541462	20041126
MX 2006006049	A	20070524	MX 2006-6049	20060526
IN 2006DN03108	A	20070824	IN 2006-DN3108	20060531
US 20080044881	A1	20080221	US 2007-580670	20070412

PRIORITY APPLN. INFO.:

US 2003-525430P	P	20031126
US 2004-545721P	P	20040218
WO 2004-US39728	W	20041126

OTHER SOURCE(S): CASREACT 143:59816; MARPAT 143:59816
GI



AB 2-[(2-Oxo-1,2-dihydro-indol-3-ylidene)methyl]pyrrole-4-carboxamide derivs.
(I) [wherein R1 = H, halo, C1-6 alkyl, C3-8 cycloalkyl, C1-6 haloalkyl,
HO, C1-6 alkoxy, NH2, C1-6 alkylamino, amide, sulfonamide, cyano,
(un)substituted C6-10 aryl; R2 = H, halo, C1-6 alkyl, C3-8 cycloalkyl,
C1-6 haloalkyl, HO, C1-6 alkoxy, C2-8 alkoxyalkyl, NH2, C1-6 alkylamino,
C6-10 arylamino; R3 = H, C1-6 alkyl, C6-10 aryl, C5-10 heteroaryl, amide;
R4-R6 = H, C1-6 alkyl; R7 = H, C1-6 alkyl, HO; R8 = HO, C1-6 alkoxy, C3-8
cycloalkoxy, NR9R10 (where R9, R10 = H, C1-6 alkyl, C1-6 hydroxyalkyl,
C1-6 dihydroxyalkyl, C1-6 alkoxy, C1-6 alkylcarboxylic acid, C1-6
alkylphosphoric acid, C1-6 alkylsulfuric acid, C1-6 hydroxyalkylcarboxylic
acid, C1-6 alkyl amide, C3-8 cycloalkyl, C5-8 heterocycloalkyl, C6-8 aryl,

C5-8 heteroaryl, C3-8 cycloalkylcarboxylic acid; or NR9R10 together forms (un)substituted (C5-C8) heterocyclic); n, m = 0-3; p = 1-3] or pharmaceutically acceptable salts, their tautomers, pharmaceutically acceptable salts of their tautomer, or prodrugs thereof are prepared. These compds. have enhanced and unexpected drug properties as inhibitors of protein kinases, in particular VEGF receptors and PDGF receptors, and are useful in treating disorders related to abnormal protein kinase activities such as cancer (no data). Thus, 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid was condensed with (4R,6R)-16-(2-aminoethyl)-2,2-dimethyl-[1,3]dioxan-4-yl)acetic acid tert-Bu ester using 3-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride and hydroxybenzotriazole in DMF at room temperature for 30 h followed by treatment with a mixture of 2 N aqueous HCl, THF, and EtOH, neutralization with aqueous NaHCO₃, extraction with Me tert-Bu ether to give (3R,5R)-7-[[5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carbonyl]amino]-3,5-dihydroxyheptanoic acid tert-Bu ester which was stirred with a mixture of aqueous NaOH solution and MeOH at

room temperature for 3 h to give (3R,5R)-7-[[5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carbonyl]amino]-3,5-dihydroxyheptanoic acid sodium salt (II).

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 11:25:28 ON 13 JUL 2009)

FILE 'REGISTRY' ENTERED AT 11:25:50 ON 13 JUL 2009

```

L1      STRUCTURE UPLOADED
L2      0 S L1
L3      0 S L1 SSS FULL
L4      STRUCTURE UPLOADED
L5      0 S L4
L6      0 S L4 SSS FULL
L7      STRUCTURE UPLOADED
L8      46 S L7
L9      853 S L8 SSS FULL
L10     STRUCTURE UPLOADED
L11     34 S L10
L12     520 S L10 SSS FULL
L13     STRUCTURE UPLOADED
L14     34 S L13
L15     513 S L13 SSS FULL

```

FILE 'HCAPLUS' ENTERED AT 11:36:37 ON 13 JUL 2009

```

L16     4 S L15
L17     0 S L16 AND PY<=2003

```

=> s 19

L18 38 L9

=> s 112

L19 4 L12

=> s 118 and py<=2003

24035901 PY<=2003
L20 8 L18 AND PY<=2003

=> s l19 and py<=2003
24035901 PY<=2003
L21 0 L19 AND PY<=2003

=> d l20 ibib abs hitstr tot

L20 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:931518 HCAPLUS
DOCUMENT NUMBER: 140:689
TITLE: Genes showing altered patterns of expression in response to inhibition of tyrosine kinases and their use in screening kinase inhibitors
INVENTOR(S): Morimoto, Alyssa; Deprimo, Samuel; O'Farrell, Anne-Marie; Smolich, Beverly D.; Manning, William C.; Walter, Sarah A.; Schilling, James Walter, Jr.; Cherrington, Julie
PATENT ASSIGNEE(S): Sugan, Inc., USA
SOURCE: PCT Int. Appl., 408 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003097854	A2	20031127	WO 2003-US15711	20030519 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003233576	A1	20031202	AU 2003-233576	20030519 <--
US 20040018528	A1	20040129	US 2003-440464	20030519
PRIORITY APPLN. INFO.:			US 2002-380872P	P 20020517
			US 2003-448874P	P 20030224
			US 2003-448922P	P 20030224
			WO 2003-US15711	W 20030519

OTHER SOURCE(S): MARPAT 140:689

AB Genes that are regulated by tyrosine kinase-dependent signal transduction pathways are identified as markers for the screening of inhibitors of kinase activity. The change in levels of either the protein or mRNA in a suitable test system may be used to assess the effectiveness of a test compound as an inhibitor of a tyrosine kinase activity. The invention also relates to novel methods, wherein a change in the level of at least one biomarker in a mammal exposed to a compound, compared to the level of the biomarker(s) in a mammal that has not been exposed to the compound, indicates whether the mammal is being exposed to, or is experiencing or will experience a therapeutic or toxic effect in response to, a compound


that inhibit tyrosine kinase activity.
 IT 627908-92-3 627908-93-4 627908-94-5
 627908-95-6
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as tyrosine kinase inhibitor; genes showing altered patterns of
 expression in response to inhibition of tyrosine kinases and their use
 in screening kinase inhibitors)
 RN 627908-92-3 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-
 ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl-
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 627908-93-4 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-
 ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl-
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



RN 627908-94-5 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-
 ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl-
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 627908-95-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl-
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



L20 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:678808 HCAPLUS

DOCUMENT NUMBER: 139:214331

TITLE: Process for preparing
aminocarbonylpyrrolylmethylideneindolinones from
indolinones, imidazolcarbonylpyrrolecarboxaldehydes,
and amines.

INVENTOR(S): Jin, Qingwu; Mauragis, Michael A.; May, Paul D.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070725	A2	20030828	WO 2003-US4520	20030214 <--
WO 2003070725	A3	20040115		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002066463 A1 20020829 WO 2002-US4407 20020215 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2475455 A1 20030828 CA 2003-2475455 20030214 <--

AU 2003216282 A1 20030909 AU 2003-216282 20030214 <--

EP 1476443 A2 20041117 EP 2003-742760 20030214

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003007721 A 20050125 BR 2003-7721 20030214

CN 1671693 A 20050921 CN 2003-803988 20030214

CN 1308326 C 20070404

JP 2005528344 T 20050922 JP 2003-569632 20030214

RU 2299209 C2 20070520 RU 2004-124711 20030214

TW 289560 B 20071111 TW 2003-92125614 20030917

IN 2004DN02019 A 20070810 IN 2004-DN2019 20040714

MX 2004006992 A 20041110 MX 2004-6992 20040719

HK 1078075 A1 20070713 HK 2005-109991 20051109

PRIORITY APPLN. INFO.:

WO 2002-US4407 A 20020215

US 2002-411732P P 20020918




US 2001-268683P P 20010215

US 2001-312361P P 20010815

WO 2003-US4520 W 20030214

OTHER SOURCE(S): CASREACT 139:214331; MARPAT 139:214331

GI



AB Title compds. [I; R1-R5 = H, alkyl, alkoxy, cycloalkyl, aryl, heterocyclyl

containing 1-3 N, S, O, aryloxy, alkaryl, alkaryloxy, halo, trihalomethyl, OH, SOR', SO2NR'R'', SO3R', SR', NO2, NR'R'', CN, COR', O2CR', NHCOR', (CH2)nCO2R', CONR'R'; R6 = NR8(CH2)mR9, NR10R11, 1-2 of the CH2 groups may be substituted by OH, halo; R8 = H, alkyl; R9 = NR10R11, OH, COR12, aryl, heterocyclyl containing 1-3 N, S, O, N+(O-)R10, NHCOR13; R10, R11 = H, alkyl, cyanoalkyl, cycloalkyl, aryl, heterocyclyl containing 1-3 N, S, O; R10R11N = (R'-substituted) 5-6 membered heterocyclyl optionally containing 1-3 addnl. N, O, S; R12 = H, OH, alkoxy, aryloxy; R13 = alkyl, haloalkyl, aralkyl; R', R'' = H, alkyl, cyanoalkyl, cycloalkyl, aryl, heterocyclyl containing 1-3 N, S, O; R'R''N = 5-6 membered heterocyclyl optionally containing 1-3 addnl. N, O, S; halo = F, Cl, Br, iodo; J = O, S, NH; 1 of K, L, M = CCOR6, the others of K, L, M = CR5, CR52, N, NR5, O, S; n, p = 0-2; m = 1-4], were prepared. The process comprises reaction of azoles (II) with X2R (R5, J, K, L, M, p are as defined above; Q = CHO, CHS, dioxolanyl, tetrahydrooxazolyl, etc.; X1 = Cl, Br; X2 = H; R = pyrrolyl, thiazolidinethionyl, oxazolidinethionyl, imidazolidinethionyl, pyrrolidinethionyl, etc.; or X1 = OH, alkoxy, PhO; X2 = imidazolecarbonyl; R = imidazolyl) to give (III); R20 = OR, R), and reaction of III with HR6 (R6 as defined above) and the corresponding indolinone. Thus, 4-(1H-imidazol-1-ylcarbonyl)-3,5-dimethyl-1H-pyrrole-2-carboxaldehyde, N,N-diethylethylenediamine, 5-fluorooxindole, Et3N, and MeCN were mixed and heated for 18 h at 60° to give 85% N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide.

IT 452105-23-6P 452105-24-7P 452105-25-8P

452105-26-9P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)


(process for preparing aminocarbonylpyrrolylmethylideneindolinones from indolinones, imidazolcarbonylpyrrolecarboxaldehydes, and amines)

RN 452105-23-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 452105-24-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 452105-25-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-26-9 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2003:334853 HCAPLUS

DOCUMENT NUMBER: 138:331677

TITLE: Treatment of acute myeloid leukemia with indolinone compounds, and preparation thereof


INVENTOR(S): O'Farrell, Ann-Marie; Cherrington, Julie

PATENT ASSIGNEE(S): Sugan, Inc., USA

SOURCE: PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035009	A2	20030501	WO 2002-US34525	20021028 <--
WO 2003035009	A3	20040318		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
TW 259081	B	20060801	TW 2002-91125049	20021025
CA 2464790	A1	20030501	CA 2002-2464790	20021028 <--
AU 2002360314	A1	20030506	AU 2002-360314	20021028 <--
AU 2002360314	B2	20070920		
US 20030130280	A1	20030710	US 2002-281266	20021028 <--
EP 1446117	A2	20040818	EP 2002-795563	20021028
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002013960	A	20040831	BR 2002-13960	20021028
JP 2005511540	T	20050428	JP 2003-537578	20021028
HU 2005000422	A2	20051128	HU 2005-422	20021028
NZ 532405	A	20051223	NZ 2002-532405	20021028
CN 101052394	A	20071010	CN 2002-822959	20021028
ZA 2004003091	A	20050114	ZA 2004-3091	20040422
MX 2004003853	A	20050217	MX 2004-3853	20040423
PRIORITY APPLN. INFO.:			US 2001-330623P	P 20011026
			WO 2002-US34525	W 20021028

OTHER SOURCE(S): MARPAT 138:331677
 GI



I

AB A method of treating acute myeloid leukemia in patient pos. for FLT-3-ITD

is described. The treatment is accomplished by administration of an indolinone compound (Markush included). Preparation of the compds. of the invention, e.g. I, is described.

IT 452104-85-7P 452104-87-9P 452105-23-6P
452105-24-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(indolinone derivative preparation for treatment of acute myeloid leukemia)

RN 452104-85-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-87-9 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-23-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 452105-24-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 452104-42-6P 452104-86-8P 452104-88-0P

452104-89-1P 452104-90-4P 452104-91-5P


452104-92-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(indolinone derivative preparation for treatment of acute myeloid leukemia)

RN 452104-42-6 HCAPLUS


CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (CA INDEX NAME)



RN 452104-86-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-88-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-89-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-90-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-91-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-
(CA INDEX NAME)


Double bond geometry as shown.



RN 452104-92-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-
(CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2003:154170 HCAPLUS

DOCUMENT NUMBER: 138:180703

TITLE: Combination therapy for the treatment of cancer

INVENTOR(S): Doshi, Parul; Cherrington, Julie

PATENT ASSIGNEE(S): Masferrer, Jaime, USA; Sugen Inc.

SOURCE: PCT Int. Appl., 217 pp.


CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015608	A2	20030227	WO 2002-US25797	20020815 <--
WO 2003015608	A3	20031030		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2457745	A1	20030227	CA 2002-2457745	20020815 <--
AU 2002329744	A1	20030303	AU 2002-329744	20020815 <--
AU 2002329744	B2	20070830		
US 20030216410	A1	20031120	US 2002-218910	20020815 <--
US 7320996	B2	20080122		
BR 2002011978	A	20040720	BR 2002-11978	20020815
CN 1541098	A	20041027	CN 2002-815912	20020815
JP 2005501843	T	20050120	JP 2003-520373	20020815
TW 230609	B	20050411	TW 2002-91118425	20020815
NZ 530792	A	20050930	NZ 2002-530792	20020815
HU 2005000424	A2	20070228	HU 2005-424	20020815
HU 2005000424	A3	20080428		
EP 1427326	B1	20081119	EP 2002-765988	20020815
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK, RO, SI				
AT 414512	T	20081215	AT 2002-765988	20020815
IN 2004DN00220	A	20060224	IN 2004-DN220	20040129
ZA 2004000849	A	20050503	ZA 2004-849	20040202
NO 2004000516	A	20040413	NO 2004-516	20040204
MX 2004001464	A	20050217	MX 2004-1464	20040216
BG 108622	A	20051031	BG 2004-108622	20040308
PRIORITY APPLN. INFO.:			US 2001-312413P	P 20010815
OTHER SOURCE(S):			WO 2002-US25797	W 20020815
MARPAT 138:180703				

GI



I


AB The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2 selective inhibitors. The protein kinase inhibitors are of the formula I where R = H, piperazin-1-ylmethyl, 4-methylpiperazin-1-ylmethyl, piperidin-1-ylmethyl, etc.; R1 = H, halo, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, etc.; R2 = hydrogen, halo, alkyl, substituted alkyl, trihalomethyl, hydroxy, alkoxy, etc.; R3 = H, halogen, alkyl, substituted alkyl, trihalomethyl, hydroxy, alkoxy, aryl, heteroaryl, etc.; R4 = H, halogen, alkyl, substituted alkyl, hydroxy, alkoxy, etc.; R5 = H, alkyl, substituted alkyl, etc.; R6 = hydrogen, alkyl, substituted alkyl, etc.; and R7 = H, alkyl, substituted alkyl, aryl, heteroaryl, etc.

IT 1064444-33-2
 RL: PRPH (Prophetic)
 (Combination therapy for the treatment of cancer)

RN 1064444-33-2 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-ethyl-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(1-hydroxyethyl)-2,4-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:927188 HCAPLUS

DOCUMENT NUMBER: 138:14005

TITLE: Preparation of 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors

INVENTOR(S): Cui, Jingrong; Ramphal, Yudhi; Liang, Congxin; Sun, Li; Wei, Chung Chen; Tang, Peng Cho

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 479 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096361	A2	20021205	WO 2002-US16841	20020530 <--

WO 2002096361 A3 20030313

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


AU 2002303892 A1 20021209 AU 2002-303892 20020530 <--
 US 20030125370 A1 20030703 US 2002-157007 20020530 <--
 US 6599902 B2 20030729

PRIORITY APPLN. INFO.:

US 2001-294544P P 20010530
 US 2001-328408P P 20011010
 WO 2002-US16641 W 20020530

OTHER SOURCE(S): MARPAT 138:14005

GI




I

AB The present invention relates to certain 5-aralkylsulfonfyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivs. (shown as I; see below for variable definitions; e.g. 2,4-dimethyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-(3Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide) that inhibit kinases (no data), in particular met kinase. Pharmaceutical compns. comprising these compds., methods of treating diseases mediated by kinases using pharmaceutical compns. comprising these compds., and methods of preparing them are also disclosed. In I: n = 0-2; m = 1-3; R1 and R2 = H or alkyl; R3, R4, and R5 = H, halo, alkyl, cycloalkyl, haloalkyl, hydroxy, alkoxy, alkoxy carbonyl, haloalkoxy, cyano, carboxy, carboxyalkyl, nitro, aryl, aryloxy, heteroaryl, heteroaryloxy, -(alkylene)-CONR10R11, -CONR10R11, or -NR10R11 (R10 is H or alkyl, and R11 is aryl, heteroaryl, heterocyclyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl, alkoxy carbonylalkyl, heteroalkyl, aralkyl, or heterocyclylalkyl wherein the alkyl chain in aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aralkyl, heteroalkyl, or heterocyclylalkyl is optionally substituted with one or two hydroxy, or R10 and R11 together with the N atom to which they are attached combine to form saturated or unsatd. heterocycloamino). R6 is H, alkyl, cycloalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl,

carboxyalkyl, heterocyclalkyl, aryl, heteroaryl, carboxy, alkoxy, carbonyl, heterocyclcarbonyl, aminoalkylcarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, -CONR10R11 or -(alkylene)-CONR10R11. R7 and R8 = H, alkyl, cycloalkyl, heterocyclalkyl, -COR12, -(alkylene)-COR12 (R12 = alkoxy, hydroxy, or heterocycle, alkylamino, dialkylamino), -SO2R14, -CONR13R14, or -(alkylene)-CONR13R14 (R13 is H or alkyl, and R14 is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl, alkoxy, carbonylalkyl, heteroalkyl, or heterocyclalkyl wherein the alkyl chain in aminoalkyl, heteroalkyl, heteroalkyl, or heterocyclalkyl is optionally substituted with one or two hydroxy group(s), or when R13 and R14 are attached to a N atom R13 and R14 together with the N atom to which they are attached form saturated or unsatd. heterocycloamino). R6 and R7 or R7 and R8 can combine to form a saturated or unsatd. 5 to 8 membered ring; and R9 is: H or alkyl; -PO(OR15)2 where each R15 = H or alkyl; -COR16 where R16 is H or alkyl; or -CH(R17)NR18R19 where R17 is H or alkyl, and R18 and R19 = H or alkyl or R18 and R19 together with the N atom to which they are attached form heterocycloamino. Although the methods of preparation are not claimed, 375 example preps. of I plus addnl. preps. of intermediates are included. [This abstract record is one of 2 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

- IT 477574-59-7P, 2,4-Dimethyl-5-(2-oxo-5-phenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-ylidenemethyl-1H-pyrrole-3-carboxylic acid (3-diethylamino-2-hydroxypropyl)amide 477574-88-2P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-(morpholin-4-yl)propyl)amide 477574-89-3P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-[1,2,3]triazol-1-ylpropyl)amide 477576-51-5P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-(pyrrolidin-1-yl)propyl)amide 477576-52-6P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-cyclopropylamino-2-hydroxypropyl)amide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of aralkylsulfonyl- and pyrrolylmethylidene-substituted indolinones as kinase inhibitors useful against cancers and other disorders)
- RN 477574-59-7 HCAPLUS
- CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-88-2 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-89-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-51-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-52-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(cyclopropylamino)-2-hydroxypropyl]-5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:658111 HCAPLUS

DOCUMENT NUMBER: 137:185408

TITLE: 3-(4-Amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors

INVENTOR(S): Guan, Huiping; Liang, Congxin; Sun, Li; Tang, Peng
Choi, Wei; Chung Chen; Mauragis, Michael A.; Vojkovsky, Tomas; Jin, Qingwu; Herrinton, Paul Matthew

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 167 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066463	A1	20020829	WO 2002-US4407	20020215 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				

	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,		
	UA, UG, US, UZ, VN, YU, ZA, ZM, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,		
	CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,		
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
CA	2438314	A1	20020829
CA	2002-2438314		20020215 <--
AU	2002247133	A1	20020904
AU	2002-247133		20020215 <--
AU	2002247133	B2	20070830
US	20030092917	A1	20030515
US	2002-76140		20020215 <--
US	6653308	B2	20031125
EP	1370554	A1	20031217
EP	2002-714897		20020215 <--
EP	1370554	B1	20051019
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,		
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
HU	2003003146	A2	20031229
HU	2003-3146		20020215 <--
HU	2003003146	A3	20070828
EE	200300385	A	20040216
EE	2003-385		20020215
BR	2002007494	A	20040427
BR	2002-7494		20020215
JP	2004522776	T	20040729
JP	2002-565978		20020215
JP	3677501	B2	20050803
CN	1529704	A	20040915
CN	2002-806680		20020215
CN	100338059	C	20070919
NZ	527572	A	20050729
NZ	2002-527572		20020215
AT	307128	T	20051115
AT	2002-714897		20020215
ES	2251580	T3	20060501
ES	2002-714897		20020215
AP	1718	A	20070228
AP	2003-2836		20020215
CA	2475455	A1	20030828
CA	2003-2475455		20030214 <--
WO	2003070725	A2	20030828
WO	2003-US4520		20030214 <--
WO	2003070725	A3	20040115
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,		
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,		
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,		
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,		
	PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,		
	UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,		
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,		
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,		
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
AU	2003216282	A1	20030909
AU	2003-216282		20030214 <--
US	20030229229	A1	20031211
US	2003-367008		20030214 <--
US	7119209	B2	20061010
EP	1476443	A2	20041117
EP	2003-742760		20030214
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,		
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
BR	2003007721	A	20050125
BR	2003-7721		20030214
CN	1671693	A	20050921
CN	2003-803988		20030214
CN	1308326	C	20070404
JP	2005528344	T	20050922
JP	2003-569632		20030214
RU	2299209	C2	20070520
RU	2004-124711		20030214
IN	2003DN01291	A	20090403
IN	2003-DN1291		20030813
NO	2003003608	A	20031014
NO	2003-3608		20030814 <--
NO	326604	B1	20090119
ZA	2003006335	A	20041115
ZA	2003-6335		20030814
HR	2003000657	B1	20061031
HR	2003-657		20030814
KR	884858	B1	20090223
KR	2003-710772		20030814
MX	2003007367	A	20050725
MX	2003-7367		20030815

BG 108098	A	20051230	BG 2003-108098	20030815
US 20040102510	A1	20040527	US 2003-656907	20030908
US 7179910	B2	20070220		
HK 1059621	A1	20060630	HK 2004-102229	20040325
ZA 2004005615	A	20050627	ZA 2004-5615	20040714
IN 2004DN02019	A	20070810	IN 2004-DN2019	20040714
MX 2004006992	A	20041110	MX 2004-6992	20040719
US 20050171357	A1	20050804	US 2005-95433	20050330
HK 1078075	A1	20070713	HK 2005-109991	20051109
US 20070027149	A1	20070201	US 2006-511981	20060828
US 7256189	B2	20070814		
US 20080045709	A1	20080221	US 2007-779807	20070718
PRIORITY APPLN. INFO.:			US 2001-268683P	P 20010215
			US 2001-312361P	P 20010815
			US 2002-76140	A3 20020215
			WO 2002-US4407	W 20020215
			US 2002-411732P	P 20020918
			US 2003-367008	A3 20030214
			WO 2003-US4520	W 20030214
			US 2003-656907	A3 20030908
			US 2006-511981	A3 20060828

OTHER SOURCE(S): MARPAT 137:185408

GI



AB Title compds. I [R1 = H, halo, alkyl, haloalkoxy, cycloalkyl, heterocyclic, OH, alkoxy, (un)esterified CO2H, (un)substituted NH2, CONH2; R2 = H, halo, alkyl, trihalomethyl, OH, alkoxy, CN, (un)substituted NH2, SO2NH2, (un)esterified CO2H, SO2R8, R8 = alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl; R3-R6 = H, alkyl; R7 = H, alkyl, aryl, heteroaryl, acyl; Z

= aryl, heteroaryl, heterocyclic, (un)substituted NH2] were prepared for use as protein kinase inhibitors in treatment of diseases, such as cancer (no data). Thus, Et 3,5-dimethyl-4-pyrrolecarboxylate was oxidized to the 5-carboxaldehyde, followed by ester hydrolysis, reaction with 5-fluoro-2-oxindole and amidation to give the amide II.


IT 375798-55-3P 452104-42-6P 452104-43-7P
 452104-44-8P 452104-45-9P 452104-46-0P
 452104-47-1P 452104-48-2P 452104-49-3P
 452104-50-6P 452104-51-7P 452104-52-8P
 452104-53-9P 452104-54-0P 452104-55-1P
 452104-56-2P 452104-57-3P 452104-58-4P
 452104-59-5P 452104-60-8P 452104-61-9P
 452104-62-0P 452104-63-1P 452104-64-2P
 452104-65-3P 452104-66-4P 452104-67-5P
 452104-68-6P 452104-69-7P 452104-70-0P
 452104-71-1P 452104-72-2P 452104-73-3P
 452104-74-4P 452104-75-5P 452104-76-6P
 452104-77-7P 452104-78-8P 452104-79-9P
 452104-80-2P 452104-81-3P 452104-82-4P
 452104-83-5P 452104-84-6P 452104-85-7P
 452104-86-8P 452104-87-9P 452104-88-0P
 452104-89-1P 452104-90-4P 452104-91-5P
 452104-92-6P 452104-93-7P 452104-94-8P
 452104-95-9P 452104-96-0P 452104-97-1P
 452104-98-2P 452104-99-3P 452105-00-9P
 452105-01-0P 452105-02-1P 452105-03-2P
 452105-04-3P 452105-05-4P 452105-06-5P
 452105-07-6P 452105-08-7P 452105-09-8P
 452105-10-1P 452105-11-2P 452105-12-3P
 452105-13-4P 452105-14-5P 452105-15-6P
 452105-16-7P 452105-17-8P 452105-18-9P
 452105-19-0P 452105-20-3P 452105-21-4P
 452105-22-5P 452105-23-6P 452105-24-7P
 452105-25-8P 452105-26-9P 452105-27-0P
 452105-28-1P 452105-29-2P 452105-30-5P
 452105-31-6P 452105-32-7P 452105-44-1P
 452105-45-2P 452105-46-3P 452105-47-4P
 452105-62-3P 452105-63-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivs. as protein kinase inhibitors)


RN 375798-55-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-42-6 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (CA INDEX NAME)




RN 452104-43-7 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)




RN 452104-44-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)



RN 452104-45-9 HCAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)



RN 452104-46-0 HCAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)

INDEX NAME)




RN 452104-47-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)




RN 452104-48-2 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)




RN 452104-49-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-
(CA INDEX NAME)




RN 452104-50-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl-
(CA INDEX NAME)




RN 452104-51-7 HCAPLUS

CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-3-phenyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-N-phenyl- (CA INDEX NAME)




RN 452104-52-8 HCAPLUS

CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-3-phenyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-methyl-2-oxo- (CA INDEX NAME)




RN 452104-53-9 HCAPLUS

CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-3-phenyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(2-hydroxyethyl)-2-oxo- (CA INDEX NAME)




RN 452104-54-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[[1,2-dihydro-5-(4-morpholinylcarbonyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-(4-fluorophenyl)-2-methyl- (CA INDEX NAME)




RN 452104-55-1 HCAPLUS

CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-3-(4-fluorophenyl)-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo- (CA INDEX NAME)




RN 452104-56-2 HCAPLUS

CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-3-(2,4-difluorophenyl)-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-N-phenyl- (CA INDEX NAME)




RN 452104-57-3 HCAPLUS

CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-3-(2,4-difluorophenyl)-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(2-hydroxyethyl)-2-oxo- (CA INDEX NAME)




RN 452104-58-4 HCAPLUS

CN 1H-Indole-5-carboxamide, 3-[[3-(4-cyanophenyl)-4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N,N-dimethyl-2-oxo- (CA INDEX NAME)




RN 452104-59-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 4-(4-cyanophenyl)-N-[3-(diethylamino)-2-hydroxypropyl]-5-[[1,2-dihydro-5-(4-morpholinylcarbonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl- (CA INDEX NAME)



RN 452104-60-8 HCAPLUS


CN 1H-Indole-5-carboxamide, 3-[[3-(4-chlorophenyl)-4-[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-N-phenyl- (CA INDEX NAME)



RN 452104-61-9 HCAPLUS


CN 1H-Indole-5-carboxamide, 3-[[3-(4-chlorophenyl)-4-[[3-(diethylamino)-2-

hydroxypropyl]amino]carbonyl]-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo- (CA INDEX NAME)




RN 452104-62-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)




RN 452104-63-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)




RN 452104-64-2 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)




RN 452104-65-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)




RN 452104-66-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)




RN 452104-67-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)




RN 452104-68-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(2,6-dimethyl-4-morpholinyl)-2-hydroxypropyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (CA INDEX NAME)




RN 452104-69-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(2,6-dimethyl-4-morpholinyl)-2-hydroxypropyl]-5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (CA INDEX NAME)




RN 452104-70-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[3-(2,6-dimethyl-4-morpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (CA INDEX NAME)




RN 452104-71-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)



RN 452104-72-2 HCAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)



RN 452104-73-3 HCAPLUS

10580670


CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)



RN 452104-74-4 HCAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (CA INDEX NAME)

10580670



RN 452104-75-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (CA INDEX NAME)




RN 452104-76-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (CA INDEX NAME)


10580670

ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (CA INDEX NAME)



RN 452104-77-7 HCAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (CA INDEX NAME)



10580670

RN 452104-78-8 HCAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-N,2,4-trimethyl-
(CA INDEX NAME)




RN 452104-79-9 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-N,2,4-dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 452104-80-2 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-[(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 452104-81-3 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 452104-82-4 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 452104-83-5 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 452104-84-6 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (CA INDEX NAME)



RN 452104-85-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



10580670


RN 452104-86-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-87-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-88-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 452104-89-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-90-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-91-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-92-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-93-7 HCAPLUS

CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-3-phenyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-N-phenyl-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-94-8 HCAPLUS

CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-3-phenyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-methyl-2-oxo-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-95-9 HCAPLUS

CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-3-phenyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(2-hydroxyethyl)-2-oxo-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-96-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-[1,2-dihydro-5-(4-morpholinylcarbonyl)-2-oxo-3H-indol-3-ylidene]methyl]-4-(4-fluorophenyl)-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-97-1 HCAPLUS

CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-3-(4-fluorophenyl)-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 452104-98-2 HCAPLUS

CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-3-(2,4-difluorophenyl)-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo-, (3Z)- (CA INDEX NAME)

yl]methylene]-2,3-dihydro-2-oxo-N-phenyl-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 452104-99-3 HCAPLUS

CN 1H-Indole-5-carboxamide, 3-[[4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-3-(2,4-difluorophenyl)-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(2-hydroxyethyl)-2-oxo-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-00-9 HCAPLUS

CN 1H-Indole-5-carboxamide, 3-[[3-(4-cyanophenyl)-4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N,N-dimethyl-2-oxo-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-01-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 4-(4-cyanophenyl)-N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-[1,2-dihydro-5-(4-morpholinylcarbonyl)-2-oxo-3H-indol-3-ylidene]methyl]-2-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-02-1 HCAPLUS

CN 1H-Indole-5-carboxamide, 3-[[3-(4-chlorophenyl)-4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-N-phenyl-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.




10580670

RN 452105-03-2 HCAPLUS

CN 1H-Indole-5-carboxamide, 3-[[3-(4-chlorophenyl)-4-[[[3-(diethylamino)-2-hydroxypropyl]amino]carbonyl]-5-methyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-(1-methylethyl)-2-oxo-, (3Z)- (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-04-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-05-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-06-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-

3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-tetrazol-2-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-07-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-08-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-09-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1H-tetrazol-1-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-10-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452105-11-2 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-hydroxypropyl]-2,4-dimethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452105-12-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[3-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-hydroxypropyl]-2,4-dimethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 452105-13-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-14-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-15-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[(2R)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-16-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 452105-17-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene]methyl]-N-[(2S)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 452105-18-9 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(3-methyl-2,5-dioxo-1-imidazolidinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 452105-19-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-20-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-21-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-22-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-23-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 452105-24-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 452105-28-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.





RN 452105-29-2 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)propyl]-2,4-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A






RN 452105-30-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 452105-31-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.




RN 452105-32-7 HCAPLUS


CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-(trifluoromethoxy)-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-[(3-oxido-1H-benzotriazol-1-yl)oxy]propyl]-2,4-dimethyl- (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 452105-44-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 452105-45-2 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 452105-46-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-chloro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-47-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-2,4-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 452105-62-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-N,2,4-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 452105-63-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[(2R)-2-hydroxy-3-(4-morpholinyl)propyl]-N,2,4-trimethyl-
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:539677 HCAPLUS

DOCUMENT NUMBER: 137:109202

TITLE: Preparation of 4-aryl substituted indolinones as
protein kinase signal transduction modulators for
inhibiting abnormal cell proliferation

INVENTOR(S): Cui, Jingrong; Zhang, Ruofei; Shen, Hong; Chu, Ji Yu;
Zhang, Fang-Jie; Koenig, Marcel; Do, Steven Huy; Li,
Xiaoyuan; Wei, Chung Chen; Tang, Peng Cho

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 560 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055517	A2	20020718	WO 2001-US48564	20011220 <--
WO 2002055517	A3	20020926		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,


GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2432114 A1 20020718 CA 2001-2432114 20011220 <--
 AU 2002248186 A1 20020724 AU 2002-248186 20011220 <--
 US 20030069297 A1 20030410 US 2001-23488 20011220 <--
 US 6677368 B2 20040113
 EP 1349852 A2 20031008 EP 2001-997065 20011220 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004518669 T 20040624 JP 2002-556186 20011220
 US 20040157909 A1 20040812 US 2003-736243 20031216
 US 6861418 B2 20050301
 PRIORITY APPLN. INFO.: US 2000-256479P P 20001220
 US 2001-23488 A3 20011220
 WO 2001-US48564 W 20011220
 OTHER SOURCE(S): MARPAT 137:109202
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = (un)substituted aryl or heteroaryl; R2 = H, halo, alkyl, alkenyl, alkynyl, heterocyclyl, etc.; R3 = (un)substituted pyrrole or cycloalkenylpyrrole], as well as pharmaceutical compns. thereof, are prepared and disclosed as compds. capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Thus II, was prepared via condensation of 4-phenyl-1,3-dihydroindol-2-one with 5-formyl-2-methyl-4-[3-(4-methylpiperazin-1-yl)propyl]-1H-pyrrole-3-carboxylic acid Et ester. I were evaluated against eight specific kinases, e.g., FGFR1, for which I possessed IC50 values (μ M) of 0.0091-2.07. The present invention also relates to methods for treating protein kinase related disorders.

IT 442559-57-1P 442560-03-4P 442560-04-5P
 442560-39-6P 442560-83-0P 442561-11-7P
 442561-12-8P 442561-13-9P 442561-76-4P
 442561-77-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compound; preparation of (aryl)(pyrrolylmethylene)indolinones as protein kinase signal transduction modulators)
 RN 442559-57-1 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-[(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 442560-03-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-4-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 442560-04-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-4-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 442560-39-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(4-[1,1'-biphenyl]-3-yl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(2H-1,2,3-triazol-2-yl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 442560-83-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-(4-(3-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 442561-11-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-4-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 442561-12-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(2-fluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-4-methyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 442561-13-9 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(3-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 442561-76-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(4-chlorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)propyl]-2,4-dimethyl- (CA INDEX NAME)


Double bond geometry as shown.



RN 442561-77-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[4-(2,6-difluorophenyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[3-(1,1-dioxido-4-thiomorpholinyl)-2-hydroxypropyl]-4-methyl- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:868415 HCAPLUS

DOCUMENT NUMBER: 136:697

TITLE: Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
Moon, Malcolm Wilson; Morozowich, Walter; Gao, Ping; Tang, Peng Cho

INVENTOR(S): Sugan, Inc., USA; Pharmacia & Upjohn Company

PATENT ASSIGNEE(S): PCT Int. Appl., 96 pp.

SOURCE: CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001090068	A2	20011129	WO 2001-US16757	20010524 <--
WO 2001090068	A3	20020606		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
TW 270545	B	20070111	TW 2001-90112409	20010523
CA 2408709	A1	20011129	CA 2001-2408709	20010524 <--
AU 2001064885	A	20011203	AU 2001-64885	20010524 <--
US 20020032204	A1	20020314	US 2001-863804	20010524 <--
US 6710067	B2	20040323		
US 20020035140	A1	20020321	US 2001-863905	20010524 <--
US 6451838	B2	20020917		
US 20020037878	A1	20020328	US 2001-863819	20010524 <--
US 6482848	B2	20021119		
EP 1301507	A2	20030416	EP 2001-939357	20010524 <--
EP 1301507	B1	20060719		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003534323	T	20031118	JP 2001-586257	20010524 <--
ES 2253385	T3	20060601	ES 2001-937687	20010524
AT 333453	T	20060815	AT 2001-939357	20010524
ES 2269416	T3	20070401	ES 2001-939357	20010524
US 20030045565	A1	20030306	US 2002-243663	20020916 <--
US 20030083363	A1	20030501	US 2002-243942	20020916 <--
US 6716870	B2	20040406		
US 20040127542	A1	20040701	US 2003-429895	20030505
US 7008943	B2	20060307		
HK 1054552	A1	20061208	HK 2003-106800	20030922
US 20040127544	A1	20040701	US 2003-743909	20031224
US 7053113	B2	20060530		
US 20050107340	A1	20050519	US 2004-774415	20040210
US 7112603	B2	20060926		
PRIORITY APPLN. INFO.:			US 2000-207000P	P 20000524
			US 2000-225045P	P 20000811
			US 2001-863804	A1 20010524
			US 2001-863819	A3 20010524
			US 2001-863905	A1 20010524
			WO 2001-US16757	W 20010524
			US 2002-243663	B1 20020916
			US 2002-243942	A1 20020916
OTHER SOURCE(S):	MARPAT 136:697			
AB	The present invention is directed to Mannich base prodrugs of certain 3-(pyrrol-2-ylmethylidene)-2-indolinone derivs. that modulate the activity of protein kinases ("PKs"). Pharmaceutical compns. comprising these compds., methods of treating diseases related to abnormal PK activity utilizing pharmaceutical compns. comprising these compds. and methods of preparing them are also disclosed.			
IT	375798-55-3P			
RL:	SPN (Synthetic preparation); PREP (Preparation)			

(Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone
derivs.)

RN 375798-55-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-(5-
fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (CA
INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l21 ibib abs tot

L21 HAS NO ANSWERS

'IBIB ABS ' IS NOT A VALID STRUCTURE FORMAT KEYWORD

Structure Formats

SIA ----- Structure Image, Attributes, and map table if it contains
data. (Default)

SIM ----- Structure Image.

SAT ----- Structure ATtributes and map table if it contains data.

SCT ----- Structure Connection Table and map table if it contains
data.

SDA ----- All Structure Data (image, attributes, connection table and
map table if it contains data).

NOS ----- NO Structure data.

ENTER STRUCTURE FORMAT (SIA), SCT, SDA, SIM, SAT, NOS:end

=> d his

(FILE 'HOME' ENTERED AT 11:25:28 ON 13 JUL 2009)

FILE 'REGISTRY' ENTERED AT 11:25:50 ON 13 JUL 2009

L1	STRUCTURE UPLOADED
L2	0 S L1
L3	0 S L1 SSS FULL
L4	STRUCTURE UPLOADED
L5	0 S L4
L6	0 S L4 SSS FULL
L7	STRUCTURE UPLOADED
L8	46 S L7
L9	853 S L8 SSS FULL
L10	STRUCTURE UPLOADED
L11	34 S L10
L12	520 S L10 SSS FULL
L13	STRUCTURE UPLOADED
L14	34 S L13

L15 513 S L13 SSS FULL

FILE 'HCAPLUS' ENTERED AT 11:36:37 ON 13 JUL 2009

L16 4 S L15
 L17 0 S L16 AND PY<=2003
 L18 38 S L9
 L19 4 S L12
 L20 8 S L18 AND PY<=2003
 L21 0 S L19 AND PY<=2003

=> d l19 ibib abs tot

L19 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1342422 HCAPLUS
 DOCUMENT NUMBER: 146:81764
 TITLE: Enhanced indolinone based protein kinase inhibitors
 and their preparation, pharmaceutical compositions and
 use in the treatment of cancer
 INVENTOR(S): Liang, Congxin; Feng, Yangbo; Vojtkovsky, Tomas
 PATENT ASSIGNEE(S): The Scripps Research Institute, USA
 SOURCE: U.S. Pat. Appl. Publ., 78pp., Cont.-in-part of Appl.
 No. PCT/US2004/39725.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060287381	A1	20061221	US 2006-441537	20060526
WO 2005053686	A1	20050616	WO 2004-US39752	20041126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.:		
	WO 2004-US39752	A2 20041126
	US 2005-685144P	P 20050526
	US 2005-754360P	P 20051228
	US 2003-525430P	P 20031126
	US 2004-545721P	P 20040218


OTHER SOURCE(S): MARPAT 146:81764
 GI

DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006127961	A1	20061130	WO 2006-US20363	20060526
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006249790	A1	20061130	AU 2006-249790	20060526
CA 2610067	A1	20061130	CA 2006-2610067	20060526
EP 1893194	A1	20080305	EP 2006-771248	20060526
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008542294	T	20081127	JP 2008-513740	20060526
MX 2007014810	A	20080221	MX 2007-14810	20071126
IN 2007DN09747	A	20080620	IN 2007-DN9747	20071217
KR 2008017058	A	20080225	KR 2007-730412	20071226
CN 101222920	A	20080716	CN 2006-80025908	20080115
PRIORITY APPLN. INFO.:			US 2005-685144P	P 20050526
			US 2005-754360P	P 20051228
			WO 2006-US20363	W 20060526
OTHER SOURCE(S):		CASREACT 146:27724; MARPAT 146:27724		
GI				



I



II

AB α -Hydroxy- ω -[5-(2-oxo-indol-3-ylidenemethyl)pyrrol-3-ylcarbonylamino]alkanoic acids and their derivs. I [wherein R1, R2 = H, halo, alkyl, etc.; R3 = H, alkyl, (hetero)aryl or amide; R4 - R6 = H or alkyl; R7 = OH, O-(alkyl), O-(cyclo)alkyl or (un)substituted amino; n = 1-3] and pharmaceutically acceptable salts, tautomers and prodrugs thereof were prepared as protein kinase inhibitors. For instance, II (R = OH) was synthesized via successive treatment of the corresponding pyrrolecarboxylic acid with HATU, amidation of the resultant active ester with Me (2S)-4-amino-2-hydroxybutyrate hydrochloride, and ester hydrolysis. Further amidation of acid II (R = OH) with amines led to a number of amides, such as II (R = NMe2, III). III had an IC50 of < 0.003 μ M against KDR in VEGFR biochem. assay. Therefore, the invented compds. are useful in treating disorders related to abnormal protein kinase activities such as cancer.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:523281 HCAPLUS

DOCUMENT NUMBER: 143:59818

TITLE: Preparation of 2-[(2-oxo-1,2-dihydro-indol-3-ylidene)methyl]pyrrole-4-carboxamide derivatives as protein kinase inhibitors

INVENTOR(S): Liang, Congxin

PATENT ASSIGNEE(S): The Scripps Research Institute, USA

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2




DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053686	A1	20050616	WO 2004-US39752	20041126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20060287381	A1	20061221	US 2006-441537	20060526
MX 2006006050	A	20070524	MX 2006-6050	20060526
PRIORITY APPLN. INFO.:			US 2003-525430P	P 20031126
			US 2004-545721P	P 20040218
			WO 2004-US39752	A2 20041126
			US 2005-685144P	P 20050526
			US 2005-754360P	P 20051228
OTHER SOURCE(S):		CASREACT 143:59818; MARPAT 143:59818		
GI				



AB The title compds. (I) [wherein R1 = H, halo, C1-6 alkyl, C3-8 cycloalkyl, C1-6 haloalkyl, HO, C1-6 alkoxy, NH2, C1-6 alkylamino, amide, sulfonamide, cyano, (un)substituted C6-10 aryl; R2 = H, halo, C1-6 alkyl, C3-8 cycloalkyl, C1-6 haloalkyl, HO, C1-6 alkoxy, C2-8 alkoxyalkyl, NH2, C1-6 alkylamino, C6-10 arylamino; R3 = H, C1-6 alkyl, C6-10 aryl, C5-10

heteroaryl, amide; R4-R6 = H, C1-6 alkyl; R7 = H, C1-6 alkyl, HO; R8 = HO, C1-6 alkoxy, C3-8 cycloalkoxy, NR9R10 (where R9, R10 = H, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 dihydroxyalkyl, C1-6 alkoxy, C1-6 alkylcarboxylic acid, C1-6 alkylphosphoric acid, C1-6 alkylsulfuric acid, C1-6 hydroxyalkylcarboxylic acid, C1-6 alkyl amide, C3-8 cycloalkyl, C5-8 heterocycloalkyl, C6-8 aryl, C5-8 heteroaryl, C3-8 cycloalkylcarboxylic acid; or NR9R10 together forms (un)substituted (C5-C8) heterocyclic; n, m = 0-3; p = 1-3) or pharmaceutically acceptable salts, their tautomers, pharmaceutically acceptable salts of their tautomer, or prodrugs thereof are prepared. These compounds have enhanced and unexpected drug properties as inhibitors of protein kinases, in particular VEGF receptors and PDGF receptors, and are useful in treating disorders related to abnormal protein kinase activities such as cancer (no data). Thus, 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid was condensed with (4R,6R)-[6-(2-aminoethyl)-2,2-dimethyl-1,3]dioxan-4-yl]acetic acid tert-Bu ester using 3-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride and hydroxybenzotriazole in DMF at room temperature for 30 h followed by treatment with a mixture of 2 N aqueous HCl, THF, and EtOH, neutralization with aqueous NaHCO₃, extraction with Me tert-Bu ether to give (3R,5R)-7-[[5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carbonyl]amino]-3,5-dihydroxyheptanoic acid tert-Bu ester which was stirred with a mixture of aqueous NaOH solution and MeOH at room temperature for 3 h to give (3R,5R)-7-[[5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carbonyl]amino]-3,5-dihydroxyheptanoic acid sodium salt (II).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2005:523237 HCAPLUS
DOCUMENT NUMBER: 143:59816
TITLE: Preparation of advanced indolinone based protein kinase inhibitors
INVENTOR(S): Liang, Congxin
PATENT ASSIGNEE(S): The Scripps Research Institute, USA
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053614	A2	20050616	WO 2004-US39728	20041126
WO 2005053614	A3	20060223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,				

SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

AU 2004294981	A1	20050616	AU 2004-294981	20041126
CA 2547066	A1	20050616	CA 2004-2547066	20041126
EP 1686987	A2	20060809	EP 2004-812287	20041126





R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
HR, IS, YU

CN 1905869	A	20070131	CN 2004-80040854	20041126
BR 2004016994	A	20070206	BR 2004-16994	20041126
JP 2007512353	T	20070517	JP 2006-541462	20041126
MX 2006006049	A	20070524	MX 2006-6049	20060526
IN 2006DN03108	A	20070824	IN 2006-DN3108	20060531
US 20080044881	A1	20080221	US 2007-580670	20070412

PRIORITY APPLN. INFO.:

US 2003-525430P	P	20031126
US 2004-545721P	P	20040218
WO 2004-US39728	W	20041126

OTHER SOURCE(S): CASREACT 143:59816; MARPAT 143:59816
GI



AB 2-[(2-Oxo-1,2-dihydro-indol-3-ylidene)methyl]pyrrole-4-carboxamide derivs.
(I) [wherein R1 = H, halo, C1-6 alkyl, C3-8 cycloalkyl, C1-6 haloalkyl,
HO, C1-6 alkoxy, NH2, C1-6 alkylamino, amide, sulfonamide, cyano,
(un)substituted C6-10 aryl; R2 = H, halo, C1-6 alkyl, C3-8 cycloalkyl,
C1-6 haloalkyl, HO, C1-6 alkoxy, C2-8 alkoxyalkyl, NH2, C1-6 alkylamino,
C6-10 arylamino; R3 = H, C1-6 alkyl, C6-10 aryl, C5-10 heteroaryl, amide;
R4-R6 = H, C1-6 alkyl; R7 = H, C1-6 alkyl, HO; R8 = HO, C1-6 alkoxy, C3-8
cycloalkoxy, NR9R10 (where R9, R10 = H, C1-6 alkyl, C1-6 hydroxyalkyl,
C1-6 dihydroxyalkyl, C1-6 alkoxy, C1-6 alkylcarboxylic acid, C1-6
alkylphosphoric acid, C1-6 alkylsulfuric acid, C1-6 hydroxyalkylcarboxylic
acid, C1-6 alkyl amide, C3-8 cycloalkyl, C5-8 heterocycloalkyl, C6-8 aryl,

C5-8 heteroaryl, C3-8 cycloalkylcarboxylic acid; or NR9R10 together forms (un)substituted (C5-C8) heterocyclic); n, m = 0-3; p = 1-3] or pharmaceutically acceptable salts, their tautomers, pharmaceutically acceptable salts of their tautomer, or prodrugs thereof are prepared. These compds. have enhanced and unexpected drug properties as inhibitors of protein kinases, in particular VEGF receptors and PDGF receptors, and are useful in treating disorders related to abnormal protein kinase activities such as cancer (no data). Thus, 5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid was condensed with (4R,6R)-[6-(2-aminoethyl)-2,2-dimethyl-[1,3]dioxan-4-yl]acetic acid tert-Bu ester using 3-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride and hydroxybenzotriazole in DMF at room temperature for 30 h followed by treatment with a mixture of 2 N aqueous HCl, THF, and EtOH, neutralization with aqueous NaHCO₃, extraction with Me tert-Bu ether to give (3R,5R)-7-[[5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carbonyl]amino]-3,5-dihydroxyheptanoic acid tert-Bu ester which was stirred with a mixture of aqueous NaOH solution and MeOH at

room temperature for 3 h to give (3R,5R)-7-[[5-(5-fluoro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carbonyl]amino]-3,5-dihydroxyheptanoic acid sodium salt (II).

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

111.87	1047.73
--------	---------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-13.12	-13.12

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 11:45:19 ON 13 JUL 2009